Raremark® has launched its patient-powered knowledge platform Xperiome™ to help the pharmaceutical industry deliver innovative new therapies faster and smarter.
By using the Xperiome platform, pharmaceutical companies can recruit and retain hard-to-reach patients in research studies, improve go-to-market strategies and evaluate the effectiveness of new treatments in a real-world setting.
“The missing puzzle piece is often the patient perspective, especially in rare disease, where patients are so much harder to find,” said Alex Garner, Chief Operations Officer. “The Xperiome platform enables pharmaceutical companies and contract research organizations to connect with these hard-to-reach communities and uncover key insights that make the drug development process smarter.”
The Xperiome platform has been created using Raremark’s domain expertise in drug development, machine learning and behavioral science. It is a growing knowledge base of patient experiences built by people affected by rare diseases, which provides a 360 degree view of rare patient journeys and allows community members to share patient-orientated guidance to researchers based on their real-world lived experiences.